keyword
MENU ▼
Read by QxMD icon Read
search

neutrophil to lymphocyte ratio in mCRPC prognosis

keyword
https://www.readbyqxmd.com/read/27368058/neutrophil-to-lymphocyte-ratio-predicts-psa-response-and-prognosis-in-prostate-cancer-a-systematic-review-and-meta-analysis
#1
Jian Cao, Xuan Zhu, Xiaokun Zhao, Xue-Feng Li, Ran Xu
An unprecedented advance has been seen in castration-resistant prostate cancer (CRPC) treatments in the past few years. With a number of novel agents were approved, there is a pressing need to develop improved prognostic biomarkers to facilitate the personalised selection and sequencing of these novel agents. Emerging evidence indicates that the neutrophil-to-lymphocyte ratio (NLR) is associated with poorer survival in patients with prostate cancer (PCa). However, the importance of the NLR for the prediction of the PSA response (PSARS) and biochemical recurrence (BCR) has been largely neglected...
2016: PloS One
https://www.readbyqxmd.com/read/26912340/prognostic-significance-of-neutrophil-to-lymphocyte-ratio-in-prostate-cancer-evidence-from-16-266-patients
#2
Xiaobin Gu, Xianshu Gao, Xiaoying Li, Xin Qi, Mingwei Ma, Shangbin Qin, Hao Yu, Shaoqian Sun, Dong Zhou, Wen Wang
This study was aimed to investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR) in patients with prostate cancer (PCa). A meta-analysis including 14 publications (15 cohorts) with 16,266 patients was performed to evaluate the association between NLR and overall survival (OS), progression-free survival (PFS)/recurrence-free survival (RFS) in PCa using hazard ratio (HR) and 95% confidence intervals (95% CI). The combining data showed that increased NLR predict poor OS (HR = 1.38, 95%CI: 1...
2016: Scientific Reports
https://www.readbyqxmd.com/read/26817900/prognostic-role-of-neutrophil-to-lymphocyte-ratio-in-prostate-cancer-a-systematic-review-and-meta-analysis
#3
REVIEW
Xiaotao Yin, Yi Xiao, Fanglong Li, Siyong Qi, Zhaoyang Yin, Jiangping Gao
Inflammation is increasingly reported to be associated with the prognosis of patients with cancers. And the prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with prostate cancer (PCa) remains inconsistent. Therefore, we conducted this systematic review and meta-analysis to obtain a more reliable assessment of prognostic significance of NLR in PCa.A comprehensive literature research regarding the association of NLR and prognosis of PCa was performed through PubMed, Embase, Cochrane Central, and Web of Science...
January 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/25538172/baseline-neutrophil-lymphocyte-ratio-nlr-is-associated-with-survival-and-response-to-treatment-with-second-line-chemotherapy-for-advanced-prostate-cancer-independent-of-baseline-steroid-use
#4
RANDOMIZED CONTROLLED TRIAL
D Lorente, J Mateo, A J Templeton, Z Zafeiriou, D Bianchini, R Ferraldeschi, A Bahl, L Shen, Z Su, O Sartor, J S de Bono
BACKGROUND: The neutrophil-lymphocyte ratio (NLR), proposed as an indicator of cancer-related inflammation, has known prognostic value in prostate cancer. We examine its association with survival (OS) and response in patients treated with second-line chemotherapy. METHODS: We analysed patients with metastatic castration-resistant prostate cancer (mCRPC) treated in the TROPIC trial, evaluating cabazitaxel versus mitoxantrone. Cox regression models were used to investigate the association of baseline NLR (BLNLR) with OS and the significance of a change in NLR count with treatment...
April 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/25515657/neutrophil-to-lymphocyte-ratio-as-a-prognostic-biomarker-for-men-with-metastatic-castration-resistant-prostate-cancer-receiving-first-line-chemotherapy-data-from-two-randomized-phase-iii-trials
#5
RANDOMIZED CONTROLLED TRIAL
R J van Soest, A J Templeton, F E Vera-Badillo, F Mercier, G Sonpavde, E Amir, B Tombal, M Rosenthal, M A Eisenberger, I F Tannock, R de Wit
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR), a marker of host inflammation, has been associated with poor outcome in several solid tumors. Here, we investigated associations of the derived NLR (dNLR) and duration of initial androgen deprivation therapy (ADT) with survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line chemotherapy. PATIENTS AND METHODS: Data from the multinational randomized phase III studies VENICE and TAX327 included a total of 2230 men with mCRPC randomized to receive first-line chemotherapy, and were used as training and validation sets, respectively...
April 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/24995769/simple-prognostic-score-for-metastatic-castration-resistant-prostate-cancer-with-incorporation-of-neutrophil-to-lymphocyte-ratio
#6
Arnoud J Templeton, Carmel Pezaro, Aurelius Omlin, Mairéad G McNamara, Raya Leibowitz-Amit, Francisco E Vera-Badillo, Gerhardt Attard, Johann S de Bono, Ian F Tannock, Eitan Amir
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR), a marker of inflammation, has been reported to be a poor prognostic indicator in prostate cancer. Here we explore the use of the NLR to establish a simple prognostic score for men with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel. METHODS: In the training cohort, the NLR and other known prognostic variables were evaluated among a cohort of chemotherapy-naïve patients treated with thrice-weekly docetaxel at the Princess Margaret Cancer Centre...
November 1, 2014: Cancer
https://www.readbyqxmd.com/read/24806399/prognostic-impact-of-the-neutrophil-to-lymphocyte-ratio-in-men-with-metastatic-castration-resistant-prostate-cancer
#7
COMPARATIVE STUDY
Guru Sonpavde, Gregory R Pond, Andrew J Armstrong, Stephen J Clarke, Janette L Vardy, Arnoud J Templeton, Shaw-Ling Wang, Jolanda Paolini, Isan Chen, Edna Chow-Maneval, Mariajose Lechuga, Matthew R Smith, M Dror Michaelson
BACKGROUND: We retrospectively evaluated the prognostic impact of neutrophil-lymphocyte ratio (NLR) as a marker for inflammatory and immune state in men with progressive metastatic castration resistant prostate cancer (mCRPC) following docetaxel. METHODS: The SUN-1120 phase III trial comparing prednisone combined with sunitinib (n = 584) or placebo (n = 289) for mCRPC following docetaxel-based chemotherapy was evaluated. The arms were combined for analysis, since no difference was observed in the primary endpoint of overall survival (OS)...
October 2014: Clinical Genitourinary Cancer
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"